Clinical trial · Interventional
ImmunoPET Imaging of Pancreatic Cancer
Development and Clinical Translation of immunoPET Imaging Probes for Pancreatic Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Pancreatic cancer remains one of the most aggressive cancer types. Target-specific targeted therapy is an attractive therapeutic alternative for the treatment of patients with a wide range of cancers, including pancreatic cancer. Companion diagnostic technique is critical for the success of targeted therapies. SHR-A1921 is a TROP2-directed antibody-drug-conjugate (ADC) approved for several clinical trials for advanced solid tumors. SHR1920 is the humanized anti-Trop2 monoclonal antibody (hIgG1) of SHR-A1921. Radio-labeling SHR1920 with radionuclide Zirconium-89 (89Zr) enables non-invasive imaging and quantification of SHR-A1921 distribution in cancer patients. Performing a \[89Zr\]Zr-DFO-SHR1920 PET scan before treatment with SHR-A1921 can evaluate tracer uptake in the primary and metastatic tumor lesions and normal organ distribution. CLND18.2 is another potential therapeutic target for pancreatic cancer. Target-specific immunoPET imaging may help identify patients more likely to benefit from targeted therapy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Neoplasms Pancreatic | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| [18F]F-RESCA-3A12 | Diagnostic Test | — | UNRESOLVED |
| [68Ga]Ga-NOTA-3A12 | Diagnostic Test | — | UNRESOLVED |
| [89Zr]Zr-DFO-SHR1920 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- ImmunoPET imaging in patients with pancreatic cancers
- description
- Enrolled pancreatic cancer patients (locally advanced or metastatic cancer) will undergo a Trop2/CLDN18.2-targeted immunoPET/CT scanning.
- interventionNames
- Diagnostic Test: [89Zr]Zr-DFO-SHR1920
- Diagnostic Test: [18F]F-RESCA-3A12
- Diagnostic Test: [68Ga]Ga-NOTA-3A12
Primary outcomes (2)
- measure
- SUV
- timeFrame
- 7 days
- description
- Standardized uptake value (SUV) of \[89Zr\]Zr-DFO-SHR1920、\[18F\]F-RESCA-3A12 or \[68Ga\]Ga-NOTA-3A12 for each primary tumor of subject or suspected metastasis.
- measure
- Biodistribution and radiation dosimetry of [89Zr]Zr-DFO-SHR1920
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 70 Years
Show eligibility criteria text
Inclusion Criteria: * Histologically confirmed diagnosis of pancreatic cancer or suspected pancreatic cancer by diagnostic imaging. * Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in this protocol. Exclusion Criteria: * Known or suspected hypersensitivity to SHR1920, DFO/RESCA/NOTA, 89Zr/18F or 68Ga or any of the excipients. * Pregnancy
References
Publications (0)
Data not yet available